Chemistry:Hetrombopag
From HandWiki
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia.[1][2][3]
It is a non-peptide small‐molecule thrombopoietin receptor agonist.[4]
In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.[4]
References
- ↑ "Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study". Annals of Translational Medicine 10 (2): 30. January 2022. doi:10.21037/atm-21-4361. PMID 35282136.
- ↑ "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia". Journal of Hematology & Oncology 14 (1): 37. February 2021. doi:10.1186/s13045-021-01047-9. PMID 33632264.
- ↑ "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood 142: 5631. 2023. doi:10.1182/blood-2023-185469.
- ↑ 4.0 4.1 "Hetrombopag: First Approval". Drugs 81 (13): 1581–1585. September 2021. doi:10.1007/s40265-021-01575-1. PMID 34357499.
 |  |
